Group 1 - The core viewpoint of the article is that Sanofi Bio (300298.SZ) is currently focused on developing its self-researched biosensing technology primarily for monitoring and managing diabetes and related chronic diseases [1] - The company has not yet ventured into the fields of neurointervention or brain-machine interfaces [1] - There are no ongoing preclinical studies specifically targeting neurochemical monitoring [1]